File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Potential use of mesenchymal stem cells (MSCs) treatment in D-Galactosamine induced acute liver failure model

TitlePotential use of mesenchymal stem cells (MSCs) treatment in D-Galactosamine induced acute liver failure model
Authors
Issue Date2007
Citation
The 7th American Transplant Congress (ATC 2007), San Francisco, CA., 5-9 May 2007. In American Journal of Transplantation, v. 7 suppl. s2, p. 323-323, abstract no. 676 How to Cite?
AbstractBACKGROUND AND AIM: Acute liver failure is characterized by severe injury of hepatocytes with a high mortality approaching 80%. Hepatocyte regeneration is often slow and the patients may die of various complications. The aim of the study is to investigate the potential of adult MSCs in bone marrow as a possible treatment in a D-Galactosamine induced acute liver failure model. METHODS: An acute liver failure model was created by a single-intraperitoneal injection of D-Galactosamine with a dosage of 700mg/kg. Adult MSCs were harvested from the femur and tibia of green fluorescent protein (GFP) transgenic Sprague Dawley rats. Cultured 5 X 106 MSCs were injected via the portal vein 24 hours after DGalactosamine administration. Liver tissues from rats were collected on 48, 72 and 96 hours respectively. Blood plasma and serum were also collected at time of sacrifice for liver function tests (LFTs). RESULT: More than 90% of MSCs expressed CD90 (marker for undifferentiated stem cells) and GFP using flow cyctometry. Transplanted MSCs could be identified in the damaged liver by D-Galactosamine using immunohistochemistry. GFP immunostaining clearly indicated. MSCs existed around the blood vessels and predominantly along the sites of injury. Serum transaminases were lower compared to control suggesting that liver damage was reduced. CONCLUSION: MSC therapy may reduce liver damage in a rat acute liver failure model. Further study will be taken to understand the mechanism of MSC therapy.
DescriptionPoster Session 1 - Acute Rejection: P12
Persistent Identifierhttp://hdl.handle.net/10722/108180

 

DC FieldValueLanguage
dc.contributor.authorLam, SPen_HK
dc.contributor.authorLau, CKen_HK
dc.contributor.authorCheung, CKYen_HK
dc.contributor.authorMan, Ken_HK
dc.contributor.authorLuk, JMCen_HK
dc.contributor.authorLo, CMen_HK
dc.date.accessioned2010-09-26T00:28:49Z-
dc.date.available2010-09-26T00:28:49Z-
dc.date.issued2007en_HK
dc.identifier.citationThe 7th American Transplant Congress (ATC 2007), San Francisco, CA., 5-9 May 2007. In American Journal of Transplantation, v. 7 suppl. s2, p. 323-323, abstract no. 676en_HK
dc.identifier.urihttp://hdl.handle.net/10722/108180-
dc.descriptionPoster Session 1 - Acute Rejection: P12-
dc.description.abstractBACKGROUND AND AIM: Acute liver failure is characterized by severe injury of hepatocytes with a high mortality approaching 80%. Hepatocyte regeneration is often slow and the patients may die of various complications. The aim of the study is to investigate the potential of adult MSCs in bone marrow as a possible treatment in a D-Galactosamine induced acute liver failure model. METHODS: An acute liver failure model was created by a single-intraperitoneal injection of D-Galactosamine with a dosage of 700mg/kg. Adult MSCs were harvested from the femur and tibia of green fluorescent protein (GFP) transgenic Sprague Dawley rats. Cultured 5 X 106 MSCs were injected via the portal vein 24 hours after DGalactosamine administration. Liver tissues from rats were collected on 48, 72 and 96 hours respectively. Blood plasma and serum were also collected at time of sacrifice for liver function tests (LFTs). RESULT: More than 90% of MSCs expressed CD90 (marker for undifferentiated stem cells) and GFP using flow cyctometry. Transplanted MSCs could be identified in the damaged liver by D-Galactosamine using immunohistochemistry. GFP immunostaining clearly indicated. MSCs existed around the blood vessels and predominantly along the sites of injury. Serum transaminases were lower compared to control suggesting that liver damage was reduced. CONCLUSION: MSC therapy may reduce liver damage in a rat acute liver failure model. Further study will be taken to understand the mechanism of MSC therapy.-
dc.languageengen_HK
dc.relation.ispartofAmerican Journal of Transplantationen_HK
dc.titlePotential use of mesenchymal stem cells (MSCs) treatment in D-Galactosamine induced acute liver failure modelen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailLam, SP: serasky@hotmail.comen_HK
dc.identifier.emailLau, CK: lauck@HKUCC-COM.hku.hken_HK
dc.identifier.emailCheung, CKY: cindycky@HKUCC-COM.hku.hken_HK
dc.identifier.emailMan, K: kwanman@hkucc.hku.hken_HK
dc.identifier.emailLuk, JMC: jmluk@hkucc.hku.hken_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.authorityMan, K=rp00417en_HK
dc.identifier.authorityLuk, JMC=rp00349en_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/j.1600-6143.2007.01811.x-
dc.identifier.hkuros137332en_HK
dc.identifier.volume7en_HK
dc.identifier.issuesuppl. s2-
dc.identifier.spage323, abstract no. 676en_HK
dc.identifier.epage323, abstract no. 676en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats